NovoCure Limited (NVCR)
USD 31.54
(-1.73%)
USD 31.54
(-1.73%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 613.92 Million USD | 19.79% |
| 2022 | 512.49 Million USD | 10.34% |
| 2021 | 464.48 Million USD | 29.94% |
| 2020 | 357.46 Million USD | 35.6% |
| 2019 | 263.62 Million USD | 30.71% |
| 2018 | 201.69 Million USD | 25.47% |
| 2017 | 160.74 Million USD | 5.81% |
| 2016 | 151.92 Million USD | 30.44% |
| 2015 | 116.47 Million USD | 36.05% |
| 2014 | 85.61 Million USD | 26.26% |
| 2013 | 67.8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 146.33 Million USD | -4.32% |
| 2024 Q2 | 149.3 Million USD | 2.03% |
| 2024 Q3 | 151.81 Million USD | 1.68% |
| 2023 FY | 613.92 Million USD | 19.79% |
| 2023 Q2 | 154.69 Million USD | 1.23% |
| 2023 Q3 | 153.47 Million USD | -0.79% |
| 2023 Q4 | 152.94 Million USD | -0.35% |
| 2023 Q1 | 152.81 Million USD | 7.23% |
| 2022 Q1 | 110.62 Million USD | -12.84% |
| 2022 Q3 | 125.86 Million USD | -5.72% |
| 2022 Q4 | 142.51 Million USD | 13.24% |
| 2022 FY | 512.49 Million USD | 10.34% |
| 2022 Q2 | 133.49 Million USD | 20.67% |
| 2021 Q4 | 126.92 Million USD | 13.37% |
| 2021 FY | 464.48 Million USD | 29.94% |
| 2021 Q1 | 108.39 Million USD | 4.51% |
| 2021 Q2 | 117.21 Million USD | 8.13% |
| 2021 Q3 | 111.95 Million USD | -4.49% |
| 2020 FY | 357.46 Million USD | 35.6% |
| 2020 Q4 | 103.72 Million USD | 16.23% |
| 2020 Q3 | 89.24 Million USD | 6.52% |
| 2020 Q2 | 83.78 Million USD | 3.8% |
| 2020 Q1 | 80.71 Million USD | 8.64% |
| 2019 Q4 | 74.29 Million USD | 13.76% |
| 2019 Q1 | 59.61 Million USD | 7.78% |
| 2019 Q2 | 64.41 Million USD | 8.05% |
| 2019 FY | 263.62 Million USD | 30.71% |
| 2019 Q3 | 65.3 Million USD | 1.39% |
| 2018 Q3 | 51.05 Million USD | 4.69% |
| 2018 Q1 | 46.56 Million USD | 9.49% |
| 2018 FY | 201.69 Million USD | 25.47% |
| 2018 Q4 | 55.31 Million USD | 8.34% |
| 2018 Q2 | 48.76 Million USD | 4.73% |
| 2017 Q1 | 36.58 Million USD | -1.5% |
| 2017 Q2 | 40.75 Million USD | 11.38% |
| 2017 Q4 | 42.52 Million USD | 4.04% |
| 2017 Q3 | 40.87 Million USD | 0.3% |
| 2017 FY | 160.74 Million USD | 5.81% |
| 2016 Q1 | 37 Million USD | 0.88% |
| 2016 Q3 | 38.82 Million USD | -0.32% |
| 2016 Q4 | 37.14 Million USD | -4.31% |
| 2016 Q2 | 38.94 Million USD | 5.24% |
| 2016 FY | 151.92 Million USD | 30.44% |
| 2015 Q1 | 23.25 Million USD | -3.82% |
| 2015 FY | 116.47 Million USD | 36.05% |
| 2015 Q3 | 27.53 Million USD | -5.06% |
| 2015 Q2 | 28.99 Million USD | 24.69% |
| 2015 Q4 | 36.68 Million USD | 33.24% |
| 2014 FY | 85.61 Million USD | 26.26% |
| 2014 Q1 | 19.16 Million USD | 0.0% |
| 2014 Q2 | 22.68 Million USD | 18.38% |
| 2014 Q3 | 19.69 Million USD | -13.2% |
| 2014 Q4 | 24.18 Million USD | 22.78% |
| 2013 FY | 67.8 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 104.27 Million USD | -488.787% |
| AngioDynamics, Inc. | 252.41 Million USD | -143.221% |
| AtriCure, Inc. | 327.05 Million USD | -87.715% |
| Avinger, Inc. | 18.63 Million USD | -3193.959% |
| Azenta, Inc. | 336.26 Million USD | -82.572% |
| BioLife Solutions, Inc. | 117.57 Million USD | -422.15% |
| The Cooper Companies, Inc. | 1.82 Billion USD | 66.356% |
| Daxor Corporation | 1.28 Million USD | -47843.835% |
| Ekso Bionics Holdings, Inc. | 24.19 Million USD | -2437.836% |
| Femasys Inc. | 15.2 Million USD | -3938.916% |
| GlucoTrack, Inc. | 7.1 Million USD | -8542.005% |
| Harvard Bioscience, Inc. | 58.58 Million USD | -947.998% |
| Hologic, Inc. | 1.34 Billion USD | 54.362% |
| ICU Medical, Inc. | 717.04 Million USD | 14.381% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 79.278% |
| KORU Medical Systems, Inc. | 26.1 Million USD | -2251.505% |
| LeMaitre Vascular, Inc. | 90.33 Million USD | -579.598% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 514583.487% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 514583.487% |
| Masimo Corporation | 867 Million USD | 29.189% |
| Microbot Medical Inc. | 9.85 Million USD | -6129.609% |
| Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | -3232.931% |
| Merit Medical Systems, Inc. | 459.92 Million USD | -33.484% |
| Nephros, Inc. | 9.78 Million USD | -6174.816% |
| NEXGEL, Inc. | 4.09 Million USD | -14888.477% |
| NEXGEL, Inc. | 4.09 Million USD | -14888.477% |
| Singular Genomics Systems, Inc. | 102.24 Million USD | -500.46% |
| OraSure Technologies, Inc. | 125.34 Million USD | -389.802% |
| Pro-Dex, Inc. | 7.37 Million USD | -8221.063% |
| Pulse Biosciences, Inc. | 43.57 Million USD | -1308.932% |
| Predictive Oncology Inc. | 15.22 Million USD | -3931.168% |
| Precision Optics Corporation, Inc. | 8.52 Million USD | -7103.944% |
| QuidelOrtho Corporation | 1.35 Billion USD | 54.702% |
| Repligen Corporation | 261.12 Million USD | -135.111% |
| Sanara MedTech Inc. | 61.12 Million USD | -904.345% |
| STAAR Surgical Company | 224.55 Million USD | -173.399% |
| Sharps Technology, Inc. | 10.12 Million USD | -5962.498% |
| Utah Medical Products, Inc. | 13.26 Million USD | -4529.575% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 65.779% |
| Jin Medical International Ltd. | 3.91 Million USD | -15571.135% |